Evidence map›Paper›PMID 32572020›Full record

Trial reportTranslational psychiatry2020

Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis.

André Schmidt, Cathy Davies, Yannis Paloyelis, Nicholas Meyer, Andrea De Micheli, Valentina Ramella-Cravaro, Umberto Provenzani, Yuta Aoki, Grazia Rutigliano, Marco Cappucciati and 12 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 5 countries.

André SchmidtDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland. andre.schmidt@unibas.ch.ORCID http://orcid.org/0000-0001-6055-8397
Cathy DaviesEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-3011-8643
Yannis PaloyelisDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0002-4029-3720
Nicholas MeyerDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Andrea De MicheliEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Valentina Ramella-CravaroEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Umberto ProvenzaniEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Yuta AokiDepartment of Psychiatry, Hamamatsu University School of Medicine, Shizuoka, Japan.
Grazia RutiglianoEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Marco CappucciatiEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Dominic OliverEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0002-8920-3407
Silvia MurguiaTower Hamlets Early Detection Service (THEDS), East London NHS Foundation Trust, London, UK.
Fernando ZelayaDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Paul AllenDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Sukhi ShergillDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Paul MorrisonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Steve WilliamsDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-4299-1941
David TaylorInstitute of Pharmaceutical Science, King's College London, London, UK.
Stefan BorgwardtDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-5792-3987
Hidenori YamasueDepartment of Psychiatry, Hamamatsu University School of Medicine, Shizuoka, Japan.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Paolo Fusar-PoliEarly Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-3582-6788
King's College London · GBUniversity of Basel · CHEast London NHS Foundation Trust · GBHamamatsu University School of Medicine · JPShowa University · JP

Funding

Medical Research Council G0901868Medical Research Council MR/P001378/1
6 · The paper itself

Abstract

Social deficits are key hallmarks of the Clinical High Risk for Psychosis (CHR-P) state and of established psychotic disorders, and contribute to impaired social functioning, indicating a potential target for interventions. However, current treatments do not significantly ameliorate social impairments in CHR-P individuals. Given its critical role in social behaviour and cognition, the oxytocinergic (OT) system is a promising target for novel interventions in CHR-P subjects. In a double-blind, placebo-controlled, crossover design, 30 CHR-P males were studied using functional magnetic resonance imaging (fMRI) on two occasions, once after 40IU self-administered intranasal OT and once after placebo. A modified version of the Sally-Anne task was used to assess brain activation during inferring others' beliefs and social emotions. The Reading the Mind in the Eyes Test was acquired prior to the first scan to test whether OT effects were moderated by baseline social-emotional abilities. OT did not modulate behavioural performances but reduced activation in the bilateral inferior frontal gyrus compared with placebo while inferring others' social emotions. Furthermore, the relationship between brain activation and task performance after OT administration was moderated by baseline social-emotional abilities. While task accuracy during inferring others' social emotion increased with decreasing activation in the left inferior frontal gyrus in CHR-P individuals with low social-emotional abilities, there was no such relationship in CHR-P individuals with high social-emotional abilities. Our findings may suggest that acute OT administration enhances neural efficiency in the inferior frontal gyrus during inferring others' social emotions in those CHR-P subjects with low baseline social-emotional abilities.

Indexed as

OxytocinPsychotic DisordersAdministration, IntranasalBrainCross-Over StudiesDouble-Blind MethodEmotionsHumansMagnetic Resonance ImagingMaleOxytocin

Identifiers

PMID32572020
PMCPMC7308367
OpenAlexW3034668579

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.